Telaprevir+VX-222: VRTX discontinued the low-dose all-oral arm (100mg BID of VX-222) of the phase-2 trial due to viral breakthrough, but is continuing the high-dose all-oral arm (400mg BID of VX-222):
The company will discontinue Arm A of this study as a result of patients meeting a pre-defined stopping rule related to viral breakthrough during the first four weeks of dosing. Arm A was designed to evaluate a two-drug regimen of VX-222 (low dose; 100 mg) and telaprevir (1,125 mg) both dosed twice daily without pegylated-interferon and ribavirin. The additional three arms of the study are continuing without modification, and no viral breakthrough has been reported in these arms.
More evidence that a two-drug all-oral HCV regimen is probably not enough to get the job done, especially when the regimen does not include a nuke.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.